Merck’s new antiviral pill to treat COVID-19 shows a lot of promise. CMS lays out how the No Surprises Act dispute resolution process will work. And non-covid research is still lagging behind pre-pandemic levels.
Hosted on Acast. See acast.com/privacy for more information.
